Palaeoproteomic analyses of dog palaeofaeces reveal a preserved dietary and host digestive proteome | Proceedings of the Royal Society B: Biological Sciences royalsocietypublishing.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from royalsocietypublishing.org Daily Mail and Mail on Sunday newspapers.
T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this.
E-Mail
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years.
However, some patients do not respond to this treatment, or they only respond for a short period, after which the disease grows back. These patients therefore need alternative therapies.
Researchers from the Faculty of Health and Medical Sciences, University of Copenhagen, have now identified a combination treatment, which could potentially benefit patients that do not respond to standard chemotherapy.